RE:RE:RE:RE:What's up?I agree SVA.V is on a long-term uptrend with rising bottoms and top since 2009 and should the biotech index drop more, Sernova's positive news to come out soon should buck the trend of any further index drop. But since Mid-2015 it actually didn't buck the trend. SVA.V actually dropped more than the index. SVA.V dropped 48% ($.40 to $.21) while the Biotech Index with IBB dropped only 40% ($400 to $240). So I'm just saying the pullback in the biotech index since Mid-2015 didn't help Sernova find new buyers, since many investors avoid all the biotech stocks if the index is falling and wait until the whole sector starts trending back up again. So this is actually a good thing I'm saying, because it looks like IBB is finished dropping based on technical analysis. That could bring new eyes and buyers to Sernova on top of any momentum from news to come this year, like the U of A end of 4 year human trial results by this summer. One little hint that the U of A trial results should be good, is that if they were bad... Sernova would not have expanded to Massachusetts for further phase human trials. If the results were terrible, they would just let the U of A trial finish up and not expand and make all the aggressive moves and applications they made in 2015. So their aggressive actions looks like the 2012 to 2016 U of A human trials went well.